- Home
- CHRS vs HITI Comparison
CHRS vs HITI Comparison
Compare CHRS & HITI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HITI
- Stock Information
- Founded
- CHRS 2010
- HITI 2009
- Country
- CHRS United States
- HITI Canada
- Employees
- CHRS N/A
- HITI N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HITI
- Sector
- CHRS Health Care
- HITI
- Exchange
- CHRS Nasdaq
- HITI Nasdaq
- Market Cap
- CHRS 191.3M
- HITI 249.3M
- IPO Year
- CHRS 2014
- HITI N/A
- Fundamental
- Price
- CHRS $1.46
- HITI $3.12
- Analyst Decision
- CHRS Strong Buy
- HITI Strong Buy
- Analyst Count
- CHRS 4
- HITI 1
- Target Price
- CHRS $5.38
- HITI $4.50
- AVG Volume (30 Days)
- CHRS 2.3M
- HITI 640.8K
- Earning Date
- CHRS 11-06-2024
- HITI 01-27-2025
- Dividend Yield
- CHRS N/A
- HITI N/A
- EPS Growth
- CHRS N/A
- HITI N/A
- EPS
- CHRS N/A
- HITI N/A
- Revenue
- CHRS $304,340,000.00
- HITI $370,017,302.00
- Revenue This Year
- CHRS $2.47
- HITI $7.52
- Revenue Next Year
- CHRS N/A
- HITI $14.03
- P/E Ratio
- CHRS N/A
- HITI N/A
- Revenue Growth
- CHRS 44.19
- HITI 9.02
- 52 Week Low
- CHRS $0.66
- HITI $1.57
- 52 Week High
- CHRS $2.97
- HITI $3.62
- Technical
- Relative Strength Index (RSI)
- CHRS 50.05
- HITI 50.05
- Support Level
- CHRS $1.44
- HITI $2.96
- Resistance Level
- CHRS $1.60
- HITI $3.23
- Average True Range (ATR)
- CHRS 0.13
- HITI 0.16
- MACD
- CHRS -0.03
- HITI -0.02
- Stochastic Oscillator
- CHRS 26.19
- HITI 37.50
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About HITI High Tide Inc.
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker's Corner Ltd., Grasscity.com, Canna Cabana Inc., and KushBar Inc. The firm has established two main segments, retail and wholesale. It generates substantial revenue from retail stores' e-commerce platforms. Geographically it serves Canada, the USA, and other international markets and earns key revenue from domestic sales.